BRPI0313880B8 - composto - Google Patents
compostoInfo
- Publication number
- BRPI0313880B8 BRPI0313880B8 BRPI0313880A BR0313880A BRPI0313880B8 BR PI0313880 B8 BRPI0313880 B8 BR PI0313880B8 BR PI0313880 A BRPI0313880 A BR PI0313880A BR 0313880 A BR0313880 A BR 0313880A BR PI0313880 B8 BRPI0313880 B8 BR PI0313880B8
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- ring
- compound
- salt
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40601202P | 2002-08-26 | 2002-08-26 | |
US46612903P | 2003-04-28 | 2003-04-28 | |
PCT/US2003/026317 WO2004017908A2 (en) | 2002-08-26 | 2003-08-21 | Calcium receptor modulating compound and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0313880A BR0313880A (pt) | 2007-11-06 |
BRPI0313880B1 BRPI0313880B1 (pt) | 2016-09-27 |
BRPI0313880B8 true BRPI0313880B8 (pt) | 2021-05-25 |
Family
ID=31949909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313880A BRPI0313880B8 (pt) | 2002-08-26 | 2003-08-21 | composto |
Country Status (12)
Country | Link |
---|---|
US (3) | US7514441B2 (pt) |
EP (1) | EP1572113B1 (pt) |
JP (1) | JP4494205B2 (pt) |
KR (1) | KR101050700B1 (pt) |
AU (1) | AU2003265585B2 (pt) |
BR (1) | BRPI0313880B8 (pt) |
CA (1) | CA2494700C (pt) |
ES (1) | ES2635838T3 (pt) |
NO (1) | NO332991B1 (pt) |
NZ (1) | NZ538223A (pt) |
PL (1) | PL382706A1 (pt) |
WO (1) | WO2004017908A2 (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2494700C (en) * | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
WO2007102531A1 (ja) * | 2006-03-08 | 2007-09-13 | Takeda Pharmaceutical Company Limited | 併用薬 |
KR20080110681A (ko) | 2006-04-20 | 2008-12-18 | 암겐 인코포레이티드 | 안정적 에멀젼 조제물 |
EP1975165A1 (de) * | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
CA2681582C (en) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
WO2008139947A1 (ja) * | 2007-05-08 | 2008-11-20 | Ajinomoto Co., Inc. | 下痢の予防又は治療剤 |
PL2197280T3 (pl) | 2007-08-27 | 2013-11-29 | Basf Se | Związki pirazolowe do zwalczania szkodników będących bezkręgowcami |
WO2009051244A1 (ja) * | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
PT2292592E (pt) * | 2008-06-05 | 2012-11-12 | Asahi Kasei Pharma Corp | Composto de sulfonamida e sua aplicação |
CA2728054A1 (en) * | 2008-06-16 | 2009-12-23 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as nk2 receptor antagonists |
US8729083B2 (en) | 2008-09-24 | 2014-05-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8853125B2 (en) | 2008-09-24 | 2014-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8809344B2 (en) | 2008-10-29 | 2014-08-19 | Apath, Llc | Compounds, compositions, and methods for control of hepatitis C viral infections |
US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
WO2011003796A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
JP2012532175A (ja) | 2009-07-06 | 2012-12-13 | ビーエーエスエフ ソシエタス・ヨーロピア | 無脊椎動物系害虫防除用ピリダジン化合物 |
EP2456308A2 (en) | 2009-07-24 | 2012-05-30 | Basf Se | Pyridine derivatives for controlling invertrebate pests |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2699577A1 (en) * | 2011-04-20 | 2014-02-26 | Glaxo Group Limited | Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
NZ707432A (en) | 2012-11-16 | 2020-01-31 | Univ Health Network | Pyrazolopyrimidine compounds |
RU2015143517A (ru) | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
EP2989106B1 (en) | 2013-04-25 | 2016-12-14 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
MX367913B (es) | 2014-03-27 | 2019-09-11 | Janssen Pharmaceutica Nv | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1. |
AU2015238296B2 (en) | 2014-03-27 | 2018-10-18 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors |
WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
EP3156405A1 (en) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
CA3009609C (en) | 2015-12-25 | 2023-09-26 | Takeda Pharmaceutical Company Limited | Prevention and treatment of heart failure |
JP7002444B2 (ja) * | 2016-03-28 | 2022-01-20 | 武田薬品工業株式会社 | 医薬 |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
CA3034705C (en) | 2016-08-31 | 2021-08-03 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
CA3061590A1 (en) * | 2017-04-27 | 2018-11-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
RU2768473C2 (ru) | 2017-04-27 | 2022-03-24 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
CN110799543A (zh) | 2017-06-26 | 2020-02-14 | 百济神州有限公司 | 肝细胞癌的免疫治疗 |
PL3652178T3 (pl) | 2017-07-14 | 2024-05-06 | F. Hoffmann-La Roche Ag | Bicykliczne związki ketonowe i sposoby ich stosowania |
US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
WO2019086494A1 (en) | 2017-10-31 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bicyclic sulfones and sulfoxides and methods of use thereof |
JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918074A (en) * | 1984-03-12 | 1990-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocycle compounds |
EP0217142A3 (en) * | 1985-09-30 | 1988-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
US4746656A (en) * | 1986-07-21 | 1988-05-24 | E. R. Squibb & Sons, Inc. | 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives |
GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
MXPA02002111A (es) | 1999-08-27 | 2002-10-31 | Abbott Lab | Compuestos de sulfonilfenilpirazol utiles como inhibidores de cox-2. |
EP1257537B1 (en) * | 2000-01-24 | 2007-05-30 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
BR0208244A (pt) | 2001-03-14 | 2004-03-02 | Gr Nenthal Gmbh | Pirazolo-e tiazolopirinidinas substituìdas |
CA2494700C (en) * | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
-
2003
- 2003-08-21 CA CA2494700A patent/CA2494700C/en not_active Expired - Lifetime
- 2003-08-21 EP EP03793273.8A patent/EP1572113B1/en not_active Expired - Lifetime
- 2003-08-21 BR BRPI0313880A patent/BRPI0313880B8/pt active IP Right Grant
- 2003-08-21 ES ES03793273.8T patent/ES2635838T3/es not_active Expired - Lifetime
- 2003-08-21 WO PCT/US2003/026317 patent/WO2004017908A2/en active Search and Examination
- 2003-08-21 NZ NZ538223A patent/NZ538223A/en not_active IP Right Cessation
- 2003-08-21 PL PL382706A patent/PL382706A1/pl not_active Application Discontinuation
- 2003-08-21 AU AU2003265585A patent/AU2003265585B2/en not_active Ceased
- 2003-08-21 US US10/525,158 patent/US7514441B2/en active Active
- 2003-08-21 KR KR1020057003335A patent/KR101050700B1/ko not_active IP Right Cessation
- 2003-08-21 JP JP2004529835A patent/JP4494205B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-15 NO NO20051328A patent/NO332991B1/no not_active IP Right Cessation
-
2008
- 2008-10-31 US US12/263,426 patent/US20090215746A1/en not_active Abandoned
-
2013
- 2013-11-25 US US14/089,747 patent/US9447100B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2635838T3 (es) | 2017-10-05 |
NO332991B1 (no) | 2013-02-11 |
BRPI0313880B1 (pt) | 2016-09-27 |
CA2494700A1 (en) | 2004-03-04 |
BR0313880A (pt) | 2007-11-06 |
JP4494205B2 (ja) | 2010-06-30 |
WO2004017908A2 (en) | 2004-03-04 |
US9447100B2 (en) | 2016-09-20 |
NO20051328L (no) | 2005-03-15 |
EP1572113A4 (en) | 2006-11-22 |
JP2006510582A (ja) | 2006-03-30 |
KR20050038641A (ko) | 2005-04-27 |
EP1572113B1 (en) | 2017-05-17 |
KR101050700B1 (ko) | 2011-07-20 |
PL382706A1 (pl) | 2007-11-26 |
US20090215746A1 (en) | 2009-08-27 |
AU2003265585B2 (en) | 2008-07-03 |
AU2003265585A1 (en) | 2004-03-11 |
US20140155416A1 (en) | 2014-06-05 |
EP1572113A2 (en) | 2005-09-14 |
US20060079536A1 (en) | 2006-04-13 |
NZ538223A (en) | 2008-03-28 |
CA2494700C (en) | 2011-06-28 |
WO2004017908A3 (en) | 2006-01-05 |
US7514441B2 (en) | 2009-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0313880B8 (pt) | composto | |
BR0213877A (pt) | Compostos orgânicos | |
BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
BRPI0407810A (pt) | composto, composição farmacêutica, ativador da glicocinase, e, medicamento | |
BR0111667A (pt) | Novos compostos | |
BR0108677A (pt) | Novos compostos | |
AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
BR0213025A (pt) | Compostos de espiro-hidantoìna úteis como agentes antiinflamatórios | |
BRPI0407591A (pt) | inibidores de transcriptase reversa de não-nucleosìdeo | |
BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
BR9809697A (pt) | Composto, uso, e processo para a preparação do mesmo, composição farmacêutica, e, processo para tratar uma doença de um corpo de animal vivo, incluindo um humano | |
BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
BRPI0512193A (pt) | entidade quìmica, composição farmacêutica, métodos de tratamento de doença cardìaca, para modular o sarcÈmero cardìaco, e para potencializar miosina cardìaca em um mamìfero, uso de uma entidade quìmica, e, método de preparação de um composto | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
DE60132309D1 (de) | Amin-derivate zur behandlung von apoptosis | |
BRPI0408704A (pt) | benzil-piridazinonas como inibidores de transcriptase reversa | |
BR0102607A (pt) | Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
BRPI0615158A8 (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto. | |
BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
DE602006010905D1 (de) | Harnstoff-derivate als calcium-rezeptor-modulatoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/00, A61K 31/473, A61K 31/519, A61K 31/53, A61K 31/551, C07D 221/04, C07D 471/04, C07D 487/04, A61P 19/08 Ipc: C07D 221/04 (2011.01), C07D 487/04 (2011.01), C07D |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 221/04 , C07D 487/04 , C07D 471/04 , A61K 31/519 , A61K 31/473 , A61K 31/551 , A61K 31/53 Ipc: A61K 31/00 (2006.01), A61K 31/473 (2006.01), A61K |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/09/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |